Tagraxofusp: Safety and Efficacy of Combing TAG with AZA and AZA+VEN
Safety and Efficacy of Combining Tagraxofusp with AZA or AZA+VEN in a Phase 1b…
EMERALD: Phase 3 Results in ER+/HER2- advanced/metastatic breast cancer (mBC)
Elacestrant, an oral selective estrogen receptor degrader (SERD), vs…
Tagraxofusp: A Multicenter Phase 1/2 Trial in Patients with Poor-Risk MF
A Multicenter Phase 1/2 Trial of Tagraxofusp in Patients with Poor-Risk MF. ASH…
Phase 1: Final Analysis of ELACESTRANT in ER+/HER2- Advanced Breast Cancer
Final analysis of phase 1 study of elacestrant (RAD1901), a novel selective…